2-(4-氨基苯基)乙酸乙酯 | 59235-35-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 2-(4-氨基苯基)乙酸乙酯
• 英文名称: 4-ethoxycarbonylmethylaniline hydrochloride
• 英文别名: (4-Amino-phenyl)-essigsaeure-aethylester; Hydrochlorid；4-aminophenylacetic acid ethyl ester hydrochloride；ethyl 4-amino-phenylacetate hydrochloride；ethyl p-aminophenylacetate hydrochloride；Ethyl 2-(4-aminophenyl)acetate hydrochloride；ethyl 2-(4-aminophenyl)acetate;hydrochloride
• CAS: 59235-35-7
• 化学式: C₁₀H₁₃NO₂*ClH
• 分子量: 215.68
• InChiKey: MXLBNYJANXBQHF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  14
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  52.3
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  2-(4-氨基苯基)乙酸乙酯 在 水 、 三乙酰氧基硼氢化钠 、 溶剂黄146 、 二异丙胺 、 lithium hydroxide 作用下， 以 四氢呋喃 、 1,2-二氯乙烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 60.0h， 生成 2-(4-(benzyl(4-phenoxybenzyl)amino)phenyl)acetic acid
  参考文献：
  名称：

  Discovery of liver selective non-steroidal glucocorticoid receptor antagonist as novel antidiabetic agents

  摘要：

  Series of benzyl-phenoxybenzyl amino-phenyl acid derivatives (8a-q) are reported as non-steroidal GR antagonist. Compound 8g showed excellent h-GR binding and potent antagonistic activity (in vitro). The lead compound 8g exhibited significant oral antidiabetic and antihyperlipidemic effects (in vivo), along with liver selectivity. These preliminary results confirm discovery of potent and liver selective passive GR antagonist for the treatment of T2DM. (C) 2012 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2012.07.078
• 作为产物：
  描述：

  对硝基苯乙酸乙酯 在 palladium on activated charcoal 盐酸 、 氢气 作用下， 以 乙醇 为溶剂， 反应 0.5h， 生成 2-(4-氨基苯基)乙酸乙酯
  参考文献：
  名称：

  5-（恶二唑基）色胺的合成和血清素能活性：5-HT1D受体的有效激动剂。

  摘要：

  描述了一系列新的5-（恶二唑基）色胺的合成和5-HT1D受体活性。研究了恶二唑3-取代基的修饰，连接链的长度（n）和胺取代基，并揭示了5-HT1D受体域中的大结合口袋。容纳恶二唑取代基如苄基而不会损失激动剂的效力或功效。在苯基或苄基间隔基团上引入极性官能团会导致亲和力和功能效能提高10倍。当杂环与吲哚偶联时，观察到最佳的5-HT1D活性，苄基磺酰胺20t和20u代表了一些已知的最有效的5-HT1D激动剂。杂环中的S取代O导致效能进一步提高。删除恶二唑N-2不会降低活性，建议在此位置仅需要一个H键受体。讨论了这些化合物对5-HT1D受体相对于其他血清素能受体的选择性。磺酰胺20t对5-HT1D的选择性比5-HT2、5-HT1C和5-HT3受体高> 1000倍，对5-HT1A受体的选择性高10倍。研究了该系列化合物的功能活性，并证明了与5-HT相当的5-HT1D受体效能和功效。

  DOI：

  10.1021/jm00063a003

文献信息

• Arylsulfonamide derivative and pharmaceutical compositions and use
  申请人：NKK Corporation

  公开号：US05650428A1

  公开（公告）日：1997-07-22

  An arylsulfonamide derivative of the formula (I): ##STR1## wherein R.sup.1 is unsubstituted phenyl or naphthyl, or phenyl substituted by 1 to 3 same or different substituents selected from the group consisting of halogen, alkyl, nitro and alkoxy, R.sup.2 is straight, branched, or branched cyclic alkyl with 1 to 15 carbon atoms, phenyl, phenyloxyl, phenyloxy substituted by one or more halogen atoms, cycloalkyl with 5 to 7 carbon atoms, indolyl, alkylthiol with 1 to 4 carbon atoms, hydroxyl, protected hydroxyl, imidazolyl, pyridyloxyl, or --OSO.sub.2 R.sup.4, R.sup.4 is straight or branched alkyl with 1 to 15 carbon atoms, or unsubstituted phenyl or thienyl, or phenyl or thienyl substituted by 1 to 3 same or different substituents of halogen, alkyl, nitro and alkoxy, R.sup.3 is hydrogen or straight or branched alkyl with 1 to 20 carbon atoms, n is an integer of 0 to 10, p is an integer of 0 to 10, X is a group of the formula --(CH.sub.2)m-A-(CH.sub.2)q-, m and q are independently an integer of 0 to 8, and A is a direct bond or phenylene, or a salt thereof; a process for manufacture thereof and a pharmaceutical composition containing same. The above compound exhibits thromboxane A.sub.2 antagonism.

  根据您的要求，以下是公式(I)的中文翻译： 一种芳基磺酰胺衍生物，其化学公式为(I)：##STR1##，其中R.sup.1为未取代的苯基或萘基，或者苯基被1到3个相同的或不同的取代基所取代，这些取代基选自卤素、烷基、硝基和烷氧基；R.sup.2为直链、支链或支链环烷基，含有1到15个碳原子，苯基，苯氧基，苯氧基被一个或多个卤素原子所取代，含有5到7个碳原子的环烷基，吲哚基，含有1到4个碳原子的烷基亚硫酰基，羟基，保护的羟基，咪唑基，吡啶氧基或--OSO.sub.2 R.sup.4；R.sup.4为直链或支链烷基，含有1到15个碳原子，或者未取代的苯基或噻吩基，或者苯基或噻吩基被1到3个相同的或不同的取代基所取代，这些取代基选自卤素、烷基、硝基和烷氧基；R.sup.3为氢或直链或支链烷基，含有1到20个碳原子；n为0到10的整数；p为0到10的整数；X为化学公式--(CH.sub.2)m-A-(CH.sub.2)q-的基团，其中m和q各自独立为0到8的整数，A为直接键或亚苯基；以及其盐；一种制造该化合物的方法以及含有该化合物的药物组合物。上述化合物展现出血栓素A.sub.2拮抗性。
• QUINAZOLINE DERIVATIVES
  申请人：Eggenweiler Hans Michael

  公开号：US20120238582A1

  公开（公告）日：2012-09-20

  Novel quinazolinamide derivatives of the formula (I), in which R 1 -R 4 and X have the meanings indicated in Claim 1 , are HSP90 inhibitors and can be used for the preparation of a medicament for the treatment of diseases in which the inhibition, regulation and/or modulation of HSP90 plays a role.

  式（I）中的新型喹唑啉酰胺衍生物，其中R1-R4和X具有权利要求书中指示的含义，是HSP90抑制剂，可用于制备用于治疗HSP90起作用的疾病的药物。
• Phenylalanine derivative and proteinase inhibitor
  申请人：Okamoto, Shosuke

  公开号：EP0284632A1

  公开（公告）日：1988-10-05

  A phenylalanine derivative having the formula (I): wherein A represents (a) H2N-, (b) or B represents (a) (b) or wherein m is 0, 1, or 2 and n is 3, 4, or 5; X represents (a) hydroxy, (b) nitro, (c) amino, (d) phenoxy which may be substituted with (i) halogen or (ii) nitro, (e) C1-C4 alkyloxy which may be substituted with (i) phenyl or (ii) benzoyl, (f) benzoyl, (g) pyridyloxy which may be substituted with (i) halogen or (ii) nitro, or (h) C1-C4 alkyl which may be substituted with halogen; Y represents or -OR3 wherein R1 and R2 are independently (a) hydrogen, (b) phenyl which may be substituted with (i) benzoyl, (ii) C1-C4 alkylcarbonyl, (iii) C1-C4 alkyl which may be further substituted with C1-C4 alkoxycarbonyl or hydroxycarbonyl, (iv) C2-Cs alkenyl which may be further substituted with hydroxycarbonyl or C1-C4 alkoxycarbonyl, (v) C1-C4 alkoxycarbonyl, or (vi) amidino, (c) pyridyl which may be substituted with halogen or carboxyl (d) imidazolyl, (e) pyrimidyl, (f) tetrazolyl, (g) thiazolyl which may be substituted with C,-C4 alkyl which may be further substituted with C1-C4 alkoxycarbonyl, (h) C1-C6 alkyl which may be substituted with C1-C4 alkoxy, C1-C4 alkoxycarbonyl, phenyl, or benzoyl, (i) CS-C7 cycloalkyl which may be substituted with C1-C4 alkoxycarbonyl or (j) R' and R2 may form, with the nitrogen atom attached thereto, (i) pyperazyl which may be substituted on the nitrogen atom with C1-C4 alkyl which may be further substituted with phenyl, (ii) piperidino which may be substituted with carboxyl or C1-C4 alkoxycarbonyl, (iii) pyrrolidyl which may be substituted with C1-C4 alkoxycarbonyl, or (iv) morpholyl; and R3 represents (a) hydrogen, (b) C1-C6 alkyl which may be substituted with (i) C1-C4 alkoxy, (ii) phenyl, or (iii) pyridyl, or (c) pyridyl; or a pharmaceutically acceptable acid salt thereof. This phenylalanine derivative is effective as a proteinase.

  具有以下式（I）的苯丙氨酸衍生物：其中A代表（a）H2N-，（b）或B代表（a）（b）或其中m为0、1或2，n为3、4或5；X代表（a）羟基，（b）硝基，（c）氨基，（d）苯氧基，其可以被（i）卤素或（ii）硝基取代，（e）C1-C4烷氧基，其可以被（i）苯基或（ii）苯甲酰基取代，（f）苯甲酰基，（g）吡啶氧基，其可以被（i）卤素或（ii）硝基取代，或（h）C1-C4烷基，其可以被卤素取代；Y代表或-OR3，其中R1和R2独立地为（a）氢，（b）苯基，其可以被（i）苯甲酰基，（ii）C1-C4烷基羰基，（iii）C1-C4烷基，其可以进一步被C1-C4烷氧羰基或羟基羰基取代，（iv）C2-Cs烯烃基，其可以进一步被羟基羰基或C1-C4烷氧羰基取代，（v）C1-C4烷氧羰基，或（vi）酰胺基，（c）吡啶基，其可以被卤素或羧基取代（d）咪唑基，（e）嘧啶基，（f）四唑基，（g）噻唑基，其可以被C1-C4烷基取代，其可以进一步被C1-C4烷氧羰基取代，（h）C1-C6烷基，其可以被C1-C4烷氧基，C1-C4烷氧羰基，苯基或苯甲酰基取代，（i）C5-C7环烷基，其可以被C1-C4烷氧羰基取代或（j）R'和R2可以与其连接的氮原子形成（i）哌嗪基，其可以在氮原子上被C1-C4烷基取代，其可以进一步被苯基取代，（ii）哌啶基，其可以被羧基或C1-C4烷氧羰基取代，（iii）吡咯基，其可以被C1-C4烷氧羰基取代，或（iv）吗啉基；R3代表（a）氢，（b）C1-C6烷基，其可以被（i）C1-C4烷氧基，（ii）苯基或（iii）吡啶基取代，或（c）吡啶；或其药学上可接受的酸盐。该苯丙氨酸衍生物作为蛋白酶具有有效性。
• Lactam derivatives
  申请人：Tanabe Seiyaku Co., Ltd.

  公开号：US04839360A1

  公开（公告）日：1989-06-13

  There is disclosed a lactam derivative of the formula: ##STR1## wherein R.sup.1 is a substituted or unsubstituted phenyl group; R.sup.2 is a substituted or unsubstituted phenyl group, a cycloalkyl group or a nitrogen-containing 6-membered heterocyclic group; Z is oxygen atom or sulfur atom; and n is an integer of 2 or 3, and a salt thereof. The above lactam derivative is novel and useful as a pharmaceutical compound.

  公开了一种公式为：##STR1## 的内酰胺衍生物，其中R.sup.1是取代或未取代的苯基；R.sup.2是取代或未取代的苯基、环烷基或含氮的6元杂环基；Z是氧原子或硫原子；n是2或3的整数，以及其盐。上述内酰胺衍生物是一种新颖且作为药物化合物有用的。
• [EN] AUTOTAXIN INHIBITORS AND USES THEREOF<br/>[FR] INHIBITEURS D'AUTOTAXINE ET LEURS UTILISATIONS
  申请人：NAT AND KAPODISTRIAN UNIV OF ATHENS

  公开号：WO2016184561A1

  公开（公告）日：2016-11-24

  Novel inhibitors of the enzyme autotaxin are described. The inhibitors contain one or two zinc-binding groups at the appropriate distance, Also described are uses thereof, such as for the inhibition of autotaxin activity and the treatment of various conditions (e.g., inflammatory conditions, cancer, obesity, autoimmune diseases).

  本文描述了一种自体脂肪酸酯酶的新型抑制剂。这些抑制剂包含一个或两个适当距离的锌结合基团。此外，还描述了这些抑制剂的用途，例如用于抑制自体脂肪酸酯酶的活性和治疗各种疾病（例如炎症性疾病、癌症、肥胖症、自身免疫性疾病）。